NewAmsterdam enters supply agreement with Menarini for obicetrapib products

NewAmsterdam Pharma Co N.V.

Supply Agreement dated Aug 12, 2025 with Menarini for obicetrapib monotherapy and obicetrapib/ezetimibe fixed-dose combo.
Subsidiary will be exclusive supplier initially; price based on cost of goods sold plus a specified mark-up.
Parties to initiate manufacturing transfer to Menarini; subsidiary grants non-exclusive license for manufacturing.
Supply term runs with License Agreement (from June 2022); subsidiary can terminate on 120 days’ notice after transfer or 2 years.
Either party may terminate for uncured material breach, insolvency, or force majeure exceeding 6 months.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.